Interview with Mal Eutick, CEO, Phebra Australia
Can you start by giving our readers a brief overview of the company’s history here and your most notable achievements? Initially the company was founded as a small distributor of…
Address: 332 Burns Bay Road, Lane Cove, NSW 2066, Australia
Tel: +61 (0) 2 9420 9199
Web: http://www.phebra.com.au/
Phebra specialises in the development, manufacture, marketing and distribution of highly specialised and innovative medicines for the hospital market.
At Phebra, our inspiration and commitment comes from providing medicines for serious and life-threatening conditions. We pride ourselves in developing and providing high quality pharmaceuticals to meet the requirements of the hospital specialty pharmaceutical market.
Phebra markets a range of pharmaceuticals in important disease areas such as anti-infectives, antidotes, diagnostic dyes and agents, oncology, pain and other specialty pharmaceuticals.
Our products are distributed in Australia, New Zealand, Asia, Canada and Europe.
At Phebra, our inspiration and commitment comes from providing medicines for serious and life-threatening conditions. We pride ourselves in developing and providing high quality pharmaceuticals to meet the requirements of the hospital specialty pharmaceutical market.
Phebra markets a range of products in the following therapeutic areas:
anti-infectives
antidotes
cardiovascular and respiratory disease
central nervous system
diagnostic dyes and agents
infusion solutions, intravenous additives and electrolyte replacement solutions
oncology and pain
vitamins
specialty pharmaceuticals
Can you start by giving our readers a brief overview of the company’s history here and your most notable achievements? Initially the company was founded as a small distributor of…
Alphapharm recently celebrated its 25th anniversary. In light of this significant milestone, would you give us a brief introduction to the company? Alphapharm started in 1982 in Brisbane with a…
What impact have the PBS reforms had on sanofi-aventis in Australia? Sanofi-aventis has one of the largest portfolios of medicines in Australia, with over 240 products in the key areas…
Would you please introduce Pretium’s specific service offerings, and the focus within these? Pretium offers a comprehensive range of integrated services across our 4 lines of business – Market Intelligence,…
What are some of the challenges facing pharmaceutical companies in Australia today? There are four major challenges within the Australian pharmaceutical industry at the moment. The increasing complexity of getting…
As ASMI President and Managing Director of Galderma, would you please give us a brief overview of the Australian OTC market and Galderma’s role therein? Galderma is a leading player…
What impact have the PBS reforms had on Amgen in Australia? From a company perspective, biotechnology companies exist in a competitive space. They have predominantly niche medicines with significant competitive…
2006 marked a major milestone, with the Pharmaceutical Industry Action Agenda transformed from a Government-industry initiative into an industry-driven agenda, and the resulting creation of the Pharmaceutical Industry Council (PIC).…
One of the hot topics in the industry is the impact of PBS reforms. Can you speak to recent influence of PBS reforms affecting Novotech’s services in Australia? In our…
Would you please introduce the PBAC and the role it plays in Australia’s pharmaceutical sector? The Pharmaceutical Benefits Advisory Committee (PBAC) is a statutory committee of the Australian government which…
Molteni was created in 1892 and progressively developed a strong manufacturing base, a very active R&D department and a growing international presence. Could you introduce the story behind such achievements?…
To begin, would you please introduce Medicines Australia to Pharmaceutical Executive readers? Medicines Australia is the association that represents the country’s research-based pharmaceutical industry. With approximately 50 members, the organization…
Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the company? P3 was not one of the main reasons why…
See our Cookie Privacy Policy Here
